Crossmark

Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405–14

Crossref DOI link: https://doi.org/10.1016/j.eururo.2017.01.013

Published Print: 2017-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Hsieh, James J.

Marker, Mahtab

Chen, David
License Information

Text and Data Mining valid from 2017-09-01
More Information

This article is maintained by: Elsevier

Article Title: Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen's Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405–14

Journal Title: European Urology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.eururo.2017.01.013

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.eururo.2016.10.007

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.eururo.2017.01.012

Content Type: simple-article

Copyright: © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Document is current

Any future updates will be listed below